TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03709407

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: cervical stimuli
Description: Manouvres Godoy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical stimuli
Description: Manouvres Godoy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: terminus
Description: Manouvres Vodder

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: terminus
Description: Manouvres Vodder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo manouvre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo manouvre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: lie down
Study: NCT00612612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT03709407

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: lie down

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: lie down
Study: NCT04020887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alertwatch - Interaction
Description: Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
Study: NCT01754155

Intervention type: RADIATION
Group type: OTHER
Intervention: RSA images
Description: All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
Study: NCT00677937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified DESMOND education and ongoing support
Description: 6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
Study: NCT01992172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Photocil for Atopic Dermatitis
Description: Photocil for Atopic Dermatitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sunscreen (SPF 2)
Description: Placebo - Sunscreen (SPF 2)
Study: NCT00315458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch applied for 7-day wear.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: Placebo to match buprenorphine transdermal patch 10 or 20.
Study: NCT01807754

Intervention type: PROCEDURE
Intervention: X-ray and ultrasound imaging scanning
Description: Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.

Intervention type: PROCEDURE
Intervention: Photoacoustic imaging scans for breast cancer screening
Description: The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
Study: NCT02291042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B+O Suppository
Study: NCT01229995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implants - zirconia abutmetns - prefabricated abutments
Study: NCT02433184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
Study: NCT02550561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Tibial Nerve Stimulation
Description: PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
Study: NCT01822860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02632149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINS Vagus Nerve Stimulator
Study: NCT02283814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topamax

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topamax
Study: NCT01797146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Reminder and Evaluation Program
Description: This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~1. Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~   * Type and duration of urinary catheter use.~  * Indication of urinary catheter _________~  * Type and duration of central venous catheter use~  * Indication of urinary catheter _________~2. Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified.
Study: NCT02696850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline alone
Description: Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
Study: NCT01016795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-metHuSCF and Filgrastim
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-metHuSCF and Filgrastim
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-metHuSCF and Filgrastim
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy plus Filgrastim
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy plus Filgrastim
Description: Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
Study: NCT00618514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright Tip Laser Fiber
Description: Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
Study: NCT01466673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol/Norgestimate (EE/NGM)
Description: Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl estradiol/Desogestrel (EE/DSG)
Description: Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
Study: NCT00921765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline single bolus dose followed by saline single bolus dose iv
Study: NCT00618514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Tip Laser Fiber
Description: Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
Study: NCT00921765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline + Ketamine
Description: Single bolus dose of saline followed by ketamine 0.2 mg/kg bw

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone + Placebo
Description: Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone + Ketamine
Description: Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
Study: NCT02007746

Intervention type: OTHER
Intervention: Liver transient elastography (Fibroscan)
Description: Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.

Intervention type: OTHER
Intervention: Liver transient elastography (Fibroscan)
Description: Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
Study: NCT01760954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally
Study: NCT03855722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: Remote Ischaemic Preconditioning

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-RIPC
Description: Sham procedure
Study: NCT02627677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg QD
Description: Ponatinib 30 mg, taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg QD
Description: Ponatinib 15 mg, taken orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 400 mg BID
Description: Nilotinib 400 mg, taken orally twice daily.
Study: NCT01954654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made compression sleeve and -gauntlet
Description: Device: Compression garments worn for a minimum of six hours per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom-made compression sleeve and -gauntlet
Description: Device: Compression garments worn for a minimum of six hours per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational information, recommendation and instruction
Description: Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational information, recommendation and instruction
Description: Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
Study: NCT02837744

Intervention type: DEVICE
Intervention: Axiostat®
Description: Axiostat Chitosan Hemostatic dressing belongs to an advanced class of wound dressing that stops bleeding within few minutes of application by providing an active mechanical barrier.
Study: NCT02886572

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery
Description: Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
Study: NCT01153633

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prontosan Wound Irrigation Solution and Prontosan Wound Gel
Description: The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline and Placebo Gel
Description: The treatment procedures (after a 1 week run-in) include:~* Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~* Secondary dressing to be a semi occlusive dressing~* Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change.
Study: NCT03783169

Intervention type: OTHER
Intervention: Cardiovascular Sonographic Assessment
Description: Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)

Intervention type: OTHER
Intervention: Cardiovascular Sonographic Assessment
Description: Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, \& radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
Study: NCT02007746

Intervention type: OTHER
Intervention: Ferriscan
Description: Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.

Intervention type: PROCEDURE
Intervention: Liver biopsy in iron overloaded subjects.
Description: Liver biopsy will be done and the results will be compared to Fibroscan results.
Study: NCT03153059

Intervention type: OTHER
Intervention: Stool frequency
Description: This study is just observational study.

Intervention type: OTHER
Intervention: Stool frequency
Description: This study is just observational study.

Intervention type: OTHER
Intervention: Stool frequency
Description: This study is just observational study.
Study: NCT03745573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empateach
Description: Empateach is a behavioural intervention for teachers.
Study: NCT03434626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP Education
Description: Decision aid and Goals of Care Designation form information administered by Navigator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
Study: NCT03224117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: inject the Drug into submental fat via subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: inject the Drug into submental fat via subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: inject the Drug into submental fat via subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: inject the Drug into submental fat via subcutaneous
Study: NCT03682627

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fenestration
Description: A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fenestration and clipping
Description: A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
Study: NCT00450177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Iron group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo group
Study: NCT03933982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Plus Vinorelbine
Description: Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
Study: NCT01570218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
Study: NCT03996382

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DPD Scintigraphy
Description: Confirms/Refutes diagnosis of cardiac amyloidosis.
Study: NCT05123248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blinded Group
Description: Participants in the blinded group will be wearing the sensor for 14 days without a reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unblinded group
Description: Participants in the non-blinded group are required to wear the CGM sensor for 14 days with an open reader. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.